Must Read, they are not telling anyone about the lab where they are infecting monkeys with Ebola
- https://www.youtube.com/embed/K3rW4K8nBb4?feature=oembedNHP (non-human primate) Animal TechnicianGaithersburg, MD
You will have to wonder not only who owns the patent on the ebloa virus, plus you will have to wonder why they are infecting animals with the virus, in the United States.
Dr. Fauci did warn something worse is coming. If you remember correctly, Dr. Fauci stated outright, while Trump was president, that there would be a pandemic during his presidency.
Never take Dr. Fauci’s words as meaningless. Look what happened with COVID-19, and he has predicted something far worse will hit the civilian population. Is this of what he spoke? EBOLA
Apply NowJob DetailsEstimated: $33,000 – $49,000 a yearBenefits
- Health insurance
- Vision insurance
- Dental insurance
Full Job Description
Piper Life Sciences is currently seeking a NHP (non-human primate) Animal Technician in Gaithersburg, MD to support a major area pre-clinical contract research organization in the development and testing of infectious disease vaccine candidates.
Responsibilities of the NHP (non-human primate) Animal Technician
- Lead efforts in viral inoculation, blood draws, IV infusion and other research-based techniques on non-human primates (NHP)
- Utilize laboratory facility to provide support to animal subjects and provide humane treatment of research animals
- Assist with other laboratory techniques such as animal necropsy or euthanasia, intubation and animal surgeries
Qualifications of the NHP (non-human primate) Animal Technician
- 1+ year experience working with mice, rats, pigs, guinea pigs, macaques, or non-human primates NHP (non-human primate experience preferred but not required)
- Experience in lieu of degree will work
Compensation for the NHP (non-human primate) Animal Technician
- Salary: Commensurate with experience
- Medical, Dental, Vision, 401k
Outbreak Response ScientistAlaka`ina Foundation Family of Companies – 3.4Fort Detrick, MD
Apply NowJob DetailsEstimated: $67,000 – $88,000 a yearBenefits
- Life insurance
- Disability insurance
- Health insurance
- Dental insurance
- Microsoft Excel
- Laboratory experience
- Clinical laboratory experience
- Communication skills
- Microsoft Word
- Bachelor’s degree
- Bachelor of Science
Full Job Description
Laulima Government Solutions, LLC is looking for a qualified Outbreak Response Scientist to provide leadership support services for the National Institute of Allergies and Infectious Disease (NIAID) in a high containment facility in Fort Detrick, MD.
Description of Responsibilities:Support activities for laboratory preparedness and response to outbreaks of high consequence viral pathogens in field settings.
Support research with refined animal models for biodefense agents and facilitate testing of human samples associated with naturally occurring outbreaks in the high containment environment.
Potentially participate in deployment rotations to international and domestic sites.
Assist with Ebola virus disease survivor surveillance and research activities in Africa.
Comply with the NIH Division of Occupational Health and Safety requirement for satisfactory completion of the Biosurety program and Select Agent program.
Play a role in ensuring that the Biosurety program promotes a security conscious culture.
Comply with the physical security, protection of the division’s property, protection of information, cyber security, agent protection, control and accountability, safe disposal and waste handling, and personal security guidelines set forth by the division’s Biosurety program.Degree/Education/Certification Requirements:
Minimum of a full 4-year course of study from an accredited college or university leading to a Bachelor of Science or higher degree.
Ability to work in BSL-4 setting
Required Skills and Experience:
3-5 years’ related experience
Must have prior laboratory experience, including running various assays (immunologic, virologic, molecular)
Experience in biochemistry or hematology.
Ability to obtain/maintain DoJ Security Risk Assessment (SRA) approval.
Must be willing to be immunized with licensed and FDA approved Investigational New Drugs (IND) recommended for persons at risk to occupational exposure of biological agents
Must be willing to participate in periodic drug screening.
Must have the ability to obtain/maintain certification in Chemical Personnel Reliability Program and/or Biological Personnel Reliability Program.
Must have the ability to obtain/maintain CDC Select Agent Program approval.
Prior experience working in BSL-2 facilities, willingness to work BSL-3, and BSL-4 conditions. Able to wear respiratory protection.
Must be willing to travel once called upon for a month at a time on average.
Desired Skills and Experience:
Experience working effectively and respectfully with diverse groups in international settings.
Familiarity with the conduct of clinical laboratory diagnostics, including molecular, immunologic, and virologic testing.
Experience with viral Select Agents is highly desired.
Good Clinical Laboratory Practice (GCLP) experience is preferred.
Proficiency in Word, Excel, and PowerPoint.
Basic understanding of laboratory information management systems (LIMS).
Demonstrate interpersonal, oral and written communication, and organizational skills.
Demonstrate ability to work independently, design experiments, and analyze data.
French language skills.
Must be a US citizen or permanent resident.
Must be able to meet the requirements for Tier 3 level investigation.
Laulima Government Solutions, LLC is a fast-growing government service provider. Employees enjoy competitive salaries; a 401K plan with company match; medical, dental, disability, and life insurance coverage; tuition reimbursement; paid time off; and 10 paid holidays. Laulima Government Solutions, LLC is proud to be an equal opportunity employer.
We are an Equal Opportunity/Affirmative Action Employer of individuals with disabilities and veterans. We are proud to state that we do not discriminate in employment decisions on the basis of race, color, religion, sex, pregnancy, sexual orientation, gender identity, national origin, age, protected veteran status, or disability status. If you are a person with a disability and you need an accommodation during the application process, please click here to request accommodation. We E-Verify all employees.
The Alaka`ina Foundation Family of Companies (FOCs) is comprised of industry-recognized government service firms designated as Native Hawaiian Organization (NHO)-owned and 8(a) certified businesses. The Family of Companies (FOCs) includes Ke`aki Technologies, Laulima Government Solutions, Kūpono Government Services, and Kapili Services, Po`okela Solutions, Kīkaha Solutions, LLC, and Pololei Solutions, LLC. Alaka`ina Foundation activities under the 501(c)3 principally benefit the youth of Hawaii through charitable efforts which includes providing innovative educational programs that combine leadership, science & technology, and environmental stewardship.
For additional information, please visit http://www.alakainafoundation.com
EBOLA RESEARCH NOW HIRINGINFECT MONKEYS WITH EBOLA IN MARYLANDhttps://leidosbiomed.csod.com/ats/careersite/JobDetails.aspx?site=4&id=1616
Clinical Budget Analyst III – Ebola Research
Job ID: req1616
Employee Type: exempt full-time
Facility: Frederick: INDUS
Location: 5705 Industry Lane, Frederick, MD 21704 USA
The Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some of the most urgent and intractable problems in the biomedical sciences in cancer and AIDS, drug development and first-in-human clinical trials, applications of nanotechnology in medicine, and rapid response to emerging threats of infectious diseases.
Our core values of accountability, compassion, collaboration, dedication, integrity, and versatility serve as a guidepost for how we do our work every day in serving the public’s interest.
Within Leidos Biomedical Research Inc., the Clinical Monitoring Research Program Directorate (CMRPD) provides high-quality comprehensive and strategic operational support to the high-profile domestic and international clinical research initiatives of the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), Clinical Center (CC), National Heart, Lung and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Mental Health (NIMH). Since its inception in 2001, CMRPD’s ability to provide rapid responses, high-quality solutions, and to recruit and retain experts with a variety of backgrounds to meet the growing research portfolios of NCI, NIAID, CC, NHLBI, NIAMS, NCATS, NINDS, and NIMH has led to the considerable expansion of the program and its repertoire of support services. CMRPD’s support services are strategically aligned with the program’s mission to provide comprehensive, dedicated support to assist National Institutes of Health (NIH) researchers in providing the highest quality of clinical research in compliance with applicable regulations and guidelines, maintaining data integrity, and protecting human subjects. For the scientific advancement of clinical research, CMRPD services include comprehensive clinical trials monitoring, regulatory, pharmacovigilance, protocol navigation and development, and programmatic and project management support for facilitating the conduct of 400+ Phase I, II, and III domestic and international trials on a yearly basis. These trials investigate the prevention, diagnosis, treatment of, and therapies for cancer, influenza, HIV, and other infectious diseases and viruses such as hepatitis C, tuberculosis, malaria, and Ebola virus; heart, lung, and blood diseases and conditions; parasitic infections; rheumatic and inflammatory diseases; and rare and neglected diseases. CMRPD’s collaborative approach to clinical research and the expertise and dedication of staff to the continuation and success of the program’s mission has contributed to improving the overall standards of public health on a global scale.
The Clinical Monitoring Research Program Directorate (CMRPD) provides support to the financial management and oversight of NIAID DCR’s clinical research studies, including Ebola, HIV, COVID and other clinical research studies. The position will compile and assist with the analysis of financial information for clinical research efforts supported within the program.
- This position is in direct support of the Ebola clinical research projects in Africa, to include all financial aspects and detailed subcontractor management
- Gathers, analyzes, prepares and summarizes recommendations for financial plans, acquisition activity, trending future requirements, operating forecasts, etc.
- Monitors and provides monthly expense analyses on complex projects/problems in which analysis of situations or data requires an evaluation of tangible and intangible variables
- Works with the Business Analyst IV, primary program managers and clinical research teams to develop internal budgets that include all projected costs applicable to the clinical research studies and projects
- Develops detailed final budgets, in conjunction with the supervisor and project teams, identifying all clinical research activities, tests, and other associated activities to be performed during the conduct of the study based on the study protocol and related documents
- Works closely with partner organizations, including subcontractors, to ensure final project/study budgets are adhered to and updated when necessary, following appropriate steps for review and approval
- Assists with performing financial forecasting and reconciliation of internal accounts
- Prepares, monitors and analyzes cost proposals, reports and staffing for review by the supervisor and/or project team
- Oversees subcontractor budgets and cost proposals in support of CMRPD’s Ebola research in Africa.
- Prepares closing financial reports and obtains proper approvals from program management
- Maintains annual budget assumption documents with up-to-date information to track for actuals, approvals and estimates at completion details
- Maintains and tracks protocol budget documentation and conducts regular audits to ensure the accuracy and completeness of these records
- Assignments may be performed independently with the support of program management staff or in conjunction with other Business Analysts within CMRPD
- Works with supervisor on complex clinical research studies where analysis requires an in-depth evaluation of variable factors
- This position is located in Frederick, Maryland
- Possession of Bachelor’s degree from an accredited college/university according to the Council for Higher Education Accreditation (CHEA) or four (4) years relevant experience in lieu of degree. Foreign degrees must be evaluated for U.S. equivalency.
- In addition to the education requirements, a minimum of five (5) years progressively responsible job-related experience
- Progressively responsible experience must demonstrate increased independence and overall responsibility for more complex projects
- Demonstrated experience with analysis of budgets and costs, including burn rates and cost projections
- Demonstrated ability of budget building and cost tracking
- Ability to collect and disseminate information in a clear, concise manner
- Ability to create Excel and database reports
- Ability to track multiple projects concurrently
- Advanced knowledge of MS Office Suite including Excel (advanced), PowerPoint (advanced), and Word (intermediate)
- Excellent research and investigative skills with a high degree of accuracy and attention to detail
- Ability to review complex documents independently and/or in collaboration with clinical research managers, and determine sufficiency of financial documentation
- Ability to obtain and maintain a security clearance
Candidates with these desired skills will be given preferential consideration:
- Experience working with the U.S. Government or as a Government Contractor
- Knowledge of governmental regulations; working knowledge of the FAR/FTR
- Budgetary and strategic planning experience and responsibilities as it relates to clinical research
- Knowledge of study design, clinical and biospecimen terms used in research studies and scientific and medical concepts and terminology
- Master’s Degee in Business Administration or related field
- Experience with ERP systems, especially IBM Cognos, Costpoint and Focuspoint
Equal Opportunity Employer (EOE) | Minority/Female/Disabled/Veteran (M/F/D/V) | Drug Free Workplace (DFW)
I received the following via email, shortly after posting that CDC has been secreting Ebola info.
Fox New’s Attkisson aired the same information, and I had posted the information yesterday, and today.
How very odd. I guess that there were probably quite a few responses after the Attkisson interview.
So suddenly CDC is going to make the information public, and we are supposed to dutifully believe all that they say?
The email says:
For Immediate Release
Monday, December 22, 2014
Contact: CDC Media Relations
Ebola epidemic continues to spread, requiring intensified effort
in the three affected West African countries
CDC Director sees some promising developments but uneven progress,
looming risks in each affected nation
After more than a year of Ebola transmission in Guinea and more than 7 months of transmission in Liberia and Sierra Leone, there is still much to be done to stop the world’s first Ebola epidemic, CDC director Tom Frieden, M.D., M.P.H reported from his second visit to the three affected nations.
Dr. Frieden yesterday returned from West Africa, where he spoke with patients and staff; met with many of CDC’s 170 staff working in each of the countries; and met with the presidents, health ministers, and Ebola leadership of each country. He described the situation as both inspiring and sobering.
“It is inspiring to see how much better the response has become in the past two months, how much international commitment there is, and, most importantly, how hard people from each of the three countries are working to stop Ebola,” Dr. Frieden said. “But it is sobering that Ebola continues to spread rapidly in Sierra Leone and that in parts of Monrovia and Conakry Ebola is spreading unabated. Improvements in contact tracing are urgently needed.”
At a telebriefing held to discuss the results of his trip to Guinea, Liberia, and Sierra Leone, Dr. Frieden described progress in some areas but continued growth in Ebola cases in other areas. Lingering unmet needs throughout the region continue to challenge response efforts.
Continual Flying of Ebola Into the United States! CDC admitted to Fox News that they are hiding the numbers of effected in US from citizens, to prevent panic!
Sunday December 21, 2014
N163PA has just filed a flight plan. It is scheduled to depart from Joint Base Andrews (KADW) at 10:45PM EST Sunday heading for Cartersville (KVPC) for an estimated arrival at 12:16AM EST.
Expected route: FLUKY DCA246 PAUKI MOL J48 ODF AWSON2
For more information visit http://flightaware.com/live/flight/N163PA
N163PA has just filed a flight plan. It is scheduled to depart from Ponta Delgada Joao Paulo II (LPPD/PDL) at 07:30PM AZOT Sunday heading for Joint Base Andrews (KADW) for an estimated arrival at 09:10PM EST.
Expected route: VMG H113 LM H124 FRS H142 04200W 05000W JEBBY VITOL ACK J62 RBV J230 COPES J75 MXE V378 BAL
For more information visit http://flightaware.com/live/flight/N163PA
Recent, Already Completed Flights:
Thursday December 18, 2014:
N163PA (GLF3) has just filed a flight plan. It is scheduled to depart from Bermuda Int’l (TXKF/BDA) at 06:00PM AST Thursday heading for Tenerife South (Reina Sofia) (GCTS/TFS) for an estimated arrival at 03:43AM WET.
Expected route: M327 06000W 05000W 04000W 03000W HIE
For more information visit http://flightaware.com/live/flight/N163PA
N163PA (GLF3) has just filed a flight plan. It is scheduled to depart from Cartersville (KVPC) at 01:30PM EST Thursday heading for Bermuda Int’l (TXKF/BDA) for an estimated arrival at 04:44PM AST.
Expected route: IRQ CHS AR12 M326 M326
N173PA (GLF3) has just filed a flight plan. It is scheduled to depart from Bermuda Int’l (TXKF/BDA) at 10:45AM AST Sunday heading for Dakar (GOOY/DKR) for an estimated arrival at 08:57PM GMT.
Expected route: BDA M327 M327 05000W 04000W R976 KILG3A GOOY
For more information visit http://flightaware.com/live/flight/N173PA
N163PA has just filed a flight plan. It is scheduled to depart from Washington Dulles Intl (KIAD) at 06:45PM EST Friday heading for Dekalb-Peachtree (KPDK) for an estimated arrival at 08:11PM EST.
Expected route: FLUKY DCA246 PAUKI MOL J48 ODF AWSON2
For more information visit http://flightaware.com/live/flight/N163PA
Potential Implications for Travel Because of Ebola in Parts of West Africa
LAST UPDATED: DECEMBER 2, 2014
The Department of State alerts U.S. citizens to screening procedures, travel restrictions, and reduced aviation transportation options in response to the outbreak of Ebola Virus Disease (EVD) in Guinea, Liberia, Sierra Leone, and Mali. This Travel Alert will expire on June 2, 2015.
Due to an outbreak of EVD in the West African nations of Liberia, Guinea, Sierra Leone, and Mali, the Centers for Disease Control and Prevention (CDC) issued Level 3 Travel Warnings for Liberia, Guinea, and Sierra Leone advising against non-essential travel and a Level 2 Travel Alert for Mali, to practice enhanced precautions for avoidance of contact with ill individuals. The Bureau of Consular Affairs’ website prominently features an Ebola Fact Sheet and links to the CDC Health Travel Warnings, Travel Alert, and general guidance about Ebola.
The World Health Organization (WHO) and CDC have also published and provided interim guidance to public health authorities, airlines, and other partners in West Africa for evaluating risk of exposure of persons coming from countries affected by EVD. Travelers should consult the U.S. Department of Homeland Security website for the most up-to-date information regarding enhanced screening procedures at five U.S. airports (Newark, New York JFK, O’Hare, Atlanta, and Dulles) for all people entering the United States from or who have traveled through the Ebola-affected countries. Travelers who exhibit symptoms indicative of possible Ebola infection may be prevented from boarding and restricted from traveling for the 21-day period. Moreover, CDC’s guidelines outline the minimum recommended procedures, and state and local governments have the power to implement more stringent procedures. Please note neither the Department of State’s Bureau of Consular Affairs nor the U.S. Embassy have authority over quarantine issues and cannot prevent a U.S. citizen from being quarantined should local health authorities overseas, or in the United States, require it. For questions about quarantine, please visit the CDC website that addresses quarantine and isolation issues.
Medical evacuation from Ebola-affected countries is very difficult, even for non-Ebola illnesses. The cost for a medical evacuation flight can exceed $200,000. We encourage U.S. citizens travelling to Ebola-affected countries to purchase travel insurance and ensure this insurance includes medical evacuation for EVD. Policy holders should confirm the availability of medical care and evacuation services at their travel destinations prior to travel.
Some local, regional, and international air carriers have curtailed or temporarily suspended service to or from Ebola-affected countries. U.S. citizens planning travel to or from these countries, in accordance with the CDC Health Travel Warnings and Health Travel Alert, should contact their airline to verify seat availability, confirm departure schedules, inquire about screening procedures, and be aware of other airline options.
The Department is aware that some countries have put in place procedures relating to the travel of individuals from or who have traveled through the affected countries, including complete travel bans. Changes to existing procedures may occur with little or no notice. Please consult your airline or the embassy of your destination country for additional information.
We strongly recommend that U.S. citizens traveling or residing abroad enroll in the Department of State’s Smart Traveler Enrollment Program (STEP). STEP enrollment allows you to receive the Department’s safety and security updates, and makes it easier for the nearest U.S. embassy or U.S. consulate to contact you in an emergency. If you do not have Internet access, enroll directly with the nearest U.S. embassy or consulate.
Regularly monitor the State Department’s website where you can find current Travel Warnings, Travel Alerts, and the Worldwide Caution, and read the Country Specific Information for your destination countries. For additional information, refer to the “Traveler’s Checklist” on the State Department’s website. Current information on safety and security can also be obtained by calling 1-888-407-4747 toll-free from within the United States and Canada, or 1-202-501-4444 from other countries. These numbers are available from 8:00 a.m. to 8:00 p.m. Eastern Time, Monday through Friday (except U.S. federal holidays). Follow us on Twitter and on Facebook.
Keep in mind, that there is no known vaccine, they say that you can be saved by blood transfusions. They have also found that the blood of survivors is for sale on the black market. So, if you survive Ebola, chances are good that you will be abducted, and your blood stolen from you. That still might not be as bad as dying from Ebola, having all your blood removed, you just fall asleep. King Obola opened up the borders, allowing sick and diseased persons from anywhere and everywhere invade our country. He then allows people from anywhere and everywhere to fly into our country. The BK and other countries have banned flights. He brought Ebola into this country with the first two cases here, one taken to Atlanta. Now, the hospital in Dallas, turns away a man, from Liberia, who shows symptoms of Ebola, and allows him to wander around in Dallas for four days. He was in contact with at lease 80 people so far. Now, he is dying in the hospital in Dallas, but has infected children who attend four different Dallas schools.
Ebola Update: New Ebola Infections Report
By Josey Wales
Ebola Patient “Zero” is now identified as Thomas Eric Duncan, pictured above, Mr Duncan carried his landlord’s sick daughter to a Liberian hospital on September 15, and boarded a flight bound for the U.S. four days later.
The pregnant woman Mr Duncan carried to the hospital, her brother and three neighbors later died of the disease But Mr Duncan wasn’t showing any signs of the virus when he boarded a plane on September 19 (most likely from Roberts International Airport, pictured right on August 27), and was therefore allowed to fly all the way to Dallas, Texas where he became the first patient diagnosed with the disease on U.S. soil.
Mr Duncan’s family are among up to 80 people being monitored after exposure to the man along with the ambulance crew who transported him to hospital.
Five of those being monitered are students that attended four different Dallas schools this week after possibly being in close contact with the Ebola patient over the weekend.
Now to Hawaii, the Department of Health has confirmed a patient is currently in isolation and undergoing testing in Honolulu.
The Hawaii Nurses Association said the person is being treated at The Queen’s Medical Center.
Officials told KHON2 Ebola is a possibility, however the unnamed patient has yet to be specifically tested for the virus.
“We are early in the investigation of a patient — very, very early — who we’re investigating that might have Ebola,” said Dr. Melissa Viray, deputy state epidemiologist. “It’s very possible that they do and they have Ebola. I think it’s also more likely that they have another condition that presents with similar symptoms.”
Dr. Viray said the patient could have a number of illnesses including Ebola, flu, malaria and typhoid.
Dr. Viray wouldn’t confirm any details about the patient, symptoms, or if the person had recently traveled to West Africa. But she did say red flags for Ebola include fever and recent travel to that area.
“Why is this person being isolated?” KHON2 asked.
“What we’ve asked the hospitals to tell us about is anyone with a travel history, and anyone with a fever. And when those things come together, we’ve asked them to be very careful and in an abundance of caution while you’re working, for whatever else might be going on, also make sure you isolate against Ebola, just in case,” she said.
“So it sounds like this person does have a fever and recently traveled to West Africa,” KHON2 asked.
“Again, I can’t be the one to confirm that,” Dr. Viray said.
The patient is currently being kept in a regular room, and anyone who goes in or out must wear protective gear, officials said.
“They’re monitoring who goes in and out of that room, and making sure that everybody is as safe as possible, while the patient is being evaluated for Ebola and what other conditions that patient might have,” Dr. Viray said.
Below you will see 3 videos, the first one is an interview with Mike Adams with NaturalNews.com, Mike walks us through the chain of events that have led to Ebola being allowed in the U.S. and what we can expect in the days to come. The second video brings to light many inconsistentcys in how the first Ebola case was handled, as you will see it’s very troubling. The third video is a update from Sierra Leone, where new infections in that country are spreading to 5 new people every hour and could rise to 10 every hour by the end of October! last is what to expect when Ebola enters the human body, once infected.
As Mike Adams also explains below, how the Ebola virus thrives in winter conditions and darkness.
Not only did Patient Zero come Liberia and inform staff of this, he also handled a person who not only had Ebola before he left Liberia, but stayed with them till they died also! But there is more in this next video.
It takes up to 21 days for symptoms of the deadly virus to show.
The death toll in West Africa from the latest Ebola outbreak has passed 3,300.
Nurses recently protested in Las Vegas, saying they are not trained to treat Ebola patients. Surveys show many Americans are afraid the Ebola virus might spread inside the U.S.
Ebola outbreak: ‘Five infected every hour’ in Sierra Leone
A leading charity has warned that a rate of five new Ebola cases an hour in Sierra Leone means healthcare demands are far outstripping supply.
Save the Children said there were 765 new cases of Ebola reported in the West African state last week, while there are only 327 beds in the country.
Experts and politicians are set to meet in London to debate a global response to the crisis.
It is the world’s worst outbreak of the virus, killing 3,338 people so far.
There have been 7,178 confirmed cases, with Sierra Leone, Liberia and Guinea suffering the most.
Save the Children says Ebola is spreading across Sierra Leone at a “terrifying rate”, with the number of new cases being recorded doubling every few weeks.
It said that even as health authorities got on top of the outbreak in one area, it spread to another.
The scale of the disease is also “assively unreported” according to the charity, because “untold numbers of children are dying anonymously at home or in the streets”.
Up to 28 September
Deaths (probable, confirmed and suspected)
- 710 Guinea
- 622 Sierra Leone
- 8 Nigeria
- Source: WHO
“We’re in a race against time,” said Justin Forsyth, the organisation’s chief executive.
Speaking on the BBC’s Today programme he said that the figure for Sierra Leone could rise to 10 people every hour before the end of the month if urgent action were not taken.
Americans have a right to be worried, this disease is already spreading out of control in the countries where it all started.
There was a lot of good information on what you can do to strengthen your immune system to prevent the spread of the disease. People should be preparing for the worst and hope for the best. This is one disease we cannot take for granted.
How our government ever allowed this to happen is unforegivable.
From Mike Adams NaturalNews, Throughout the course of human history, governments — even those that claimed to be benevolent — have killed millions of their own people in horrible fashion through the use of what were essentially weapons of mass destruction. A new historical review by Dr. Stefan Riedel, MD, PhD, for Baylor University Medical Center documents some of those uses, but there are other examples as well that Natural Newsfound in its own research.
Dr. Riedel’s review was spurred in part by the continuing threat of global terrorism and, in some current conflicts, the use of weapons of mass destruction against civilian populations.
But in addition to the standard threats — chemical and conventional weapons – there should be additional concerns about non-traditional, biological threats, and the current deadly Ebola virus outbreak serves as a reminder that pandemics can also be unleashed on populations as a means of decimating them.
The historical review noted:
Because of the increased threat of terrorism, the risk posed by various microorganisms as biological weapons needs to be evaluated and the historical development and use of biological agents better understood. Biological warfare agents may be more potent than conventional and chemical weapons.
Biological warfare has been used for 2,500 years
In the past century especially, there has been substantial progress in the fields of biotechnology and biochemistry, progress that has “simplified the development and production” of biological and chemical weapons. Also, Dr. Riedel’s review found that the field of genetic engineering is most likely the deadliest of all.
“Ease of production and the broad availability of biological agents and technical know how have led to a further spread of biological weapons and an increased desire among developing countries to have them,” the review said. “The threat of bioterrorism is real and significant; it is neither in the realm of science fiction nor confined to our nation.”
Early in our history, men learned how to kill one another using incurable, untreatable sickness as a biological weapon. As early as 600 B.C., the use of infectious diseases was recognized as a way to impact, with deadly results, entire armies and the populations that supported them. Indeed, biowarfare has been used for some 2,500 years, according to a 1995 study:
The techniques of delivery and weaponization of biological warfare agents have gradually evolved from the catapulting of plague victims to the deliberate use of infected clothes, insect vectors, and specialized weapon systems.
“The crude use of filth and cadavers, animal carcasses, and contagion had devastating effects and weakened the enemy,” Dr. Riedel’s review added.
Another tactic adopted by warring factions was the poisoning of water sources of the opposing military force — a tactic that was continued often through the many European wars, as well as the American Civil War. The tactic has been used into and throughout the 20th century as well.
Middle Ages and more technological advances.
Military tacticians and leaders during the Middle Ages understood that bioweapons — infectious diseases — could be deployed against opposing armies and their supporting civilian populations.
For example, in 1346 during the siege of Caffa, a strongly fortified seaport controlled by the Genoese (now, the region is known as Feodosia, which is in Crimea, recently annexed by Russia), the assaulting Tartars fell victim to a plague epidemic. But the Tartars used it to gain military advantage; they catapulted cadavers of the deceased into the city, which then led to an outbreak of plague there. That forced the Genoese forces to retreat.
An epidemic of plague, known also as the Black Death, followed and continued to sweep through Europe, the Near East and North Africa during the 14th century. It has been called the worst pandemic in recorded history.
“The siege of Caffa is a powerful reminder of the terrible consequences when diseases are used as weapons,” said the review.
The 14th century plague killed more than 25 million Europeans, and there were other instances where disease and poisons were used during warfare, the historical review said.
In more recent times, other diseases have been used as biological weapons, most notably smallpox. Francisco Pizarro, for instance, reportedly gave native South Americans disease-contaminated clothing in the 15th century; also, during the French and Indian War in North America, the commander of British forces, Sir Jeffrey Amherst, suggested that the smallpox virus should be deliberately introduced into the Native American population hostile to the Crown, as a way of diminishing resistance.
Bioweapons in the New World
“An outbreak of smallpox in Fort Pitt led to a significant generation of fomites and provided Amherst with the means to execute his plan,” the review said, continuing:
On June 24, 1763, Captain Ecuyer, one of Amherst’s subordinate officers, provided the Native Americans with smallpox-laden blankets from the smallpox hospital. He recorded in his journal: “I hope it will have the desired effect.” As a result, a large outbreak of smallpox occurred among the Indian tribes in the Ohio River Valley.
World War I saw the first industrialized use of chemical warfare — which was eventually banned by international treaty — but there was also talk of usingbiological warfare. German military planners considered shipping horses tainted with the anthrax and glanders bacteria to the United States and other allied countries. Also, “the same agents were used to infect Romanian sheep that were designated for export to Russia,” the review said. Germany was also suspected of making plans to send cholera to Italy and plague to parts of Russia.
A League of Nations committee cleared Germany of any biological warfare in 1924 but noted that the country used chemical warfare.
Continued research and fear of use in the 20th century
By the time World War II began, a number of countries had begun substantial research into biological weapons, according to Dr. Riedel’s review:
Various allegations and countercharges clouded the events during and after World War II. Japan conducted biological weapons research from approximately 1932 until the end of World War II. The program was under the direction of Shiro Ishii (1932-1942) and Kitano Misaji (1942-1945). Several military units existed for research and development of biological warfare.
More than 10,000 prisoners were believed to have died during their captivity in Japanese prison camps as a result of experimentation with biological warfare agents.
After World War II, biowarfare programs expanded, and that included programs in the United States, but these also involved research into countermeasure programs aimed at defeating a biological attack. By 1972, however, most nations signed onto a UN-sponsored treaty, the “Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction,” which bans development and deployment of biological weapons.
Today, terrorists could deploy bioweapons
As recently as the first Gulf War in 1991, however, there were fears that biological weapons could be employed during combat. “Coalition forces prepared in 1990-1991 for potential biological and chemical warfare by training in protective masks and equipment, exercising decontamination procedures, receiving extensive education on possible detection procedures, and immunizing troops against potential biological warfare threats,” Dr. Riedel’s review said.
Since then, research into bio-agents has continued, as global terrorism fears multiply with the rise of numerous non-state actors. Even today, the Federal Emergency Management Agency, the Department of Homeland Security and the Pentagon’s NORTHCOM (Northern Command, which is responsible for protecting the U.S. homeland), have all warned that biological warfare is still a very real possibility. Officials cite the immediate post-9/11 incidents in 2001 involving anthrax spores sent to targets through the mail as examples.
Learn all these details and more at the FREE online Pandemic Preparedness course at www.BioDefense.com
What does Ebola do to the immune system?
Once the virus enters the body, it targets several types of immune cells that represent the first line of defense against invasion. It infects dendritic cells, which normally display signals of an infection on their surfaces to activate T lymphocytes—the white blood cells that could destroy other infected cells before the virus replicates further. With defective dendritic cells failing to give the right signal, the T cells don’t respond to infection, and neither do the antibodies that depend on them for activation. The virus can start replicating immediately and very quickly.
Ebola, like many viruses, works in part by inhibiting interferon—a type of molecule that cells use to hinder further viral reproduction. In a new study published today in Cell Host & Microbe, researchers found that one of Ebola’s proteins, called VP24, binds to and blocks a transport protein on the surface of immune cells that plays an important role in the interferon pathway.
Curiously, lymphocytes themselves don’t become infected with the virus, but a series of other factors—a lack of stimulation from some cells and toxic signals from others—prevent these primary immune cells from putting up a fight.
How does Ebola cause hemorrhaging?
As the virus travels in the blood to new sites, other immune cells called macrophages eat it up. Once infected, they release proteins that trigger coagulation, forming small clots throughout the blood vessels and reducing blood supply to organs. They also produce other inflammatory signaling proteins and nitric oxide, which damage the lining of blood vessels, causing them to leak. Although this damage is one of the main symptoms of infection, not all patients exhibit external hemorrhaging—bleeding from the eyes, nose, or other orifices.
Does the virus target certain organs?
Ebola triggers a system-wide inflammation and fever and can also damage many types of tissues in the body, either by prompting immune cells such as macrophages to release inflammatory molecules or by direct damage: invading the cells and consuming them from within. But the consequences are especially profound in the liver, where Ebola wipes out cells required to produce coagulation proteins and other important components of plasma. Damaged cells in the gastrointestinal tract lead to diarrhea that often puts patients at risk of dehydration. And in the adrenal gland, the virus cripples the cells that make steroids to regulate blood pressure and causes circulatory failure that can starve organs of oxygen.
What ultimately kills Ebola patients?
Damage to blood vessels leads to a drop in blood pressure, and patients die from shock and multiple organ failure.
Why do some people survive infection?
Patients fare better with supportive care, including oral or intravenous rehydration that can buy time for the body to fight off infection. But studies on blood samples from patients during the 2000 outbreak of a different Ebola strain in Uganda have also identified genes and other markers that seem to be predictive of survival.
Patients who recovered had higher levels of activated T cells in their blood and had certain variants of a gene that codes for surface proteins that white blood cells use to communicate. Earlier this year, researchers found a new association between survival and levels of sCD40L, a protein produced by platelets that could be part of the body’s attempt to repair damaged blood vessels. The authors note that markers like sCD40L could suggest new therapies that augment the repair mechanisms most important for survival.
*Correction, 15 August, 1:51 p.m.: This article has been corrected to note that nitric oxide, not nitrous oxide, damages blood vessels.
*The Ebola Files: Given the current Ebola outbreak, unprecedented in terms of number of people killed and rapid geographic spread, Science and Science Translational Medicinehave made a collection of research and news articles on the viral disease freely available to researchers and the general public.
This is a must read link: The Report Global To The President 2000. Author Jimmy Carter! It reads like something right out of the movie “Outbreak” Could this all have been planned?
UPDATE: This video from Sept 9th tells the rest of the story!